Compare NetApp Inc. (NTAP) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs ResMed Inc. — how do they compare? NetApp Inc. trades at $231.55 (market cap $45.38B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: NetApp Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and ResMed Inc. for 51 Days on average.
| NTAP | RMD | |
|---|---|---|
Market Cap | $45.38B | $31.89B |
Volume | 2,264,311 | 618,314 |
Sector | Technology | Health |
52-Week High | $235.84 | $277.88 |
52-Week Low | $94.11 | $182.82 |
Typical Hold Time | 57 Days | 51 Days |
Enterprise Value | $44.34B | $31.24B |
Dividend Yield | 0.9% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $235.84, up 3.23% today, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows bullish technical signals with support near $233 and resistance at $239. Fundamentals are robust with a 70.63% gross margin and 19.19% net income margin, though valuation multiples like the 33.3 P/E are elevated. Recent news highlights strategic AI partnerships and product launches, including Novus storage for AI infrastructure, driving positive sentiment.
Outlook is positive given earnings momentum and AI-driven growth, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed with a $219.30 price target below current levels, suggesting caution despite bullish technicals. Institutional ownership trends and cash flow improvements support stability, but investors should weigh growth prospects against premium pricing.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
